Results 121 to 130 of about 12,191 (186)

Transcriptomic signatures in Gaucher disease subtypes: A systems biology perspective. [PDF]

Mol Genet Metab Rep
Elahimanesh M, Ganjali R, Najafi M.
europepmc   +1 more source

Patient-specific midbrain organoids with CRISPR correction recapitulate neuronopathic Gaucher disease phenotypes and enable evaluation of novel therapies. [PDF]

Elife
Lin Y, Liou B, Fannin V, Adler S, Mayhew CN, Hammonds JE, Hu YC, Tchieu J, Zhang W, Zhao X, Beres RL, Setchell KDR, Kaynak A, Qi X, Feldman RA, Sun Y.   +15 more
europepmc   +1 more source

Natural-History Mapping of Lysosomal Storage Disorders (LSDs): Gaucher Disease as a Model for Precision Care. [PDF]

J Inherit Metab Dis
Ain NU, Vaishnaw M, Mistry PK.
europepmc   +1 more source

HEPES in Cell Culture Alters the Multi-Omics Profile Exhibited by Gaucher Disease Fibroblasts. [PDF]

J Cell Biochem
Corazolla EM, Schomakers BV, Trętowicz MM, Hermans J, van Weeghel M, Vaz FM, Pras-Raves ML, Vlugt KG, Beers-Stet FS, Goorden SMI, Jansen-Meijer J, Janssens GE, Hollak CEM, Houtkooper RH, van Kuilenburg ABP.   +14 more
europepmc   +1 more source

Gaucher disease, state of the art and perspectives. [PDF]

J Intern Med
Camou F, Berger MG.
europepmc   +1 more source

Serum hepcidin as a biomarker of treatment response in Gaucher disease. [PDF]

Mol Genet Metab Rep
Koppe T, Pinheiro FC, Siebert M, Basgalupp S, Daudt LE, Schwartz IVD.   +5 more
europepmc   +1 more source

Adverse events signals of enzyme replacement drugs of Gaucher disease: insights from FAERS database analysis. [PDF]

Front Med (Lausanne)
Jiao J, Li Z, Gao L, Wu Y, Zhu X.
europepmc   +1 more source

Crossing the barrier: nanomedicine as a frontier therapy for neuropathic Gaucher disease type 3. [PDF]

Ann Med Surg (Lond)
Saif M, Nasir A, Shafique S, Fatima M, Talha M.   +4 more
europepmc   +1 more source

Genomic Structural Equation Modeling Provides an Initial View of the Genetic Architecture Related to Type 1 Gaucher Disease. [PDF]

Hum Mutat
Ren S, Du M, Liu J, Li B, Liu J, Lang X.
europepmc   +1 more source

Cytotoxic lymphocyte effector function is unaffected in patients with Gaucher disease. [PDF]

Front Immunol
Zou J, Noori T, Walterfang M, Szer J, Trapani JA, Voskoboinik I.   +5 more
europepmc   +1 more source